The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis
Tóm tắt
CA 19-9 has been used with questionable accuracy to aid diagnosis of cholangiocarcinoma complicating primary sclerosing cholangitis. We aimed to characterize the test properties of CA 19-9 and of a change in CA 19-9 over time in predicting cholangiocarcinoma. Charts of 208 patients were reviewed. Fourteen patients had cholangiocarcinoma. Median CA 19-9 was higher with cholangiocarcinoma (15 vs. 290 U/ml, p < 0.0001). A cutoff of 129 U/ml provided: sensitivity 78.6%, specificity 98.5%, adjusted positive predictive value 56.6% and negative predictive value 99.4%. The median change over time was 664 U/ml in cholangiocarcinoma compared to 6.7 U/ml in primary sclerosing cholangitis alone (p < 0.0001). A cutoff of 63.2 U/ml for change in CA 19-9 provided: sensitivity 90%, specificity 98% and positive predictive value 42%. Only 2 patients with cholangiocarcinoma were the candidates for curative therapy. In conclusion, the positive predictive value of an elevated CA 19-9 was 56.6%; only advanced cases were detected by this method.
Tài liệu tham khảo
Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H: Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51(Suppl 6):VI1–VI9, 2002
Patel T: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33(6):1353–1357, 2001
Chapman RW: Risk factors for biliary tract carcinogenesis. Ann Oncol 10(Suppl 4):308–311, 1999
Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ, Jr, LaRusso NF: Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 213(1):21–25, 1991
Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, Prytz H, Sandberg-Gertzen H, Wallerstedt S, Lindberg G: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38(4):610–615, 1996
Aadland E, Schrumpf E, Fausa O, Elgjo K, Heilo A, Aakhus T, Gjone E: Primary sclerosing cholangitis: A long-term follow-up study. Scand J Gastroenterol 22(6):655–664, 1987
Bergquist A, Glaumann H, Persson B, Broome U: Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: A case-control study. Hepatology 27(2):311–316, 1998
Broome U, Lofberg R, Veress B, Eriksson LS: Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential. Hepatology 22(5):1404–1408, 1995
Siqueira E, Schoen RE, Silverman W, Martin J, Rabinovitz M, Weissfeld JL, Abu-Elmaagd K, Madariaga JR, Slivka A, Martini J: Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc 56(1):40–47, 2002
Rogers SA, Podolsky DK: Predicting cholangiocarcinoma in patients with primary sclerosing cholangitis: An analysis of the serological marker CA 19-9. Hepatology 19(2):543–545, 1994
Fisher A, Theise ND, Min A, Mor E, Emre S, Pearl A, Schwartz ME, Miller CM, Sheiner PA: CA19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation. Liver Transpl Surg 1(2):94–98, 1995
Reeves ME, DeMatteo RP: Genes and viruses in hepatobiliary neoplasia. Semin Surg Oncol 19(2):84–93, 2000
Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA: The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem 35(Pt 1):99–103, 1998
Nichols JC, Gores GJ, LaRusso NF, Wiesner RH, Nagorney DM, Ritts RE, Jr.: Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc 68(9):874–879, 1993
Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R: Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 108(3):865–869, 1995
Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, McCashland TM, Reddy KR, Zervos X, Anbari MA, Hoen H: Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study. Hepatology 31(1):7–11, 2000
Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ: The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95(1):204–207, 2000
Bjornsson E, Kilander A, Olsson R: CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver 19(6):501–508, 1999
Hultcrantz R, Olsson R, Danielsson A, Jarnerot G, Loof L, Ryden BO, Wahren B, Broome U: A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 30(4):669–673, 1999
Mann DV, Edwards R, Ho S, Lau WY, Glazer G: Elevated tumour marker CA19-9: Clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 26(5):474–479, 2000
Giannini E, Borro P, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Risso D, Lantieri PB, Antonucci A, Boccato M, Milone S, Testa R: Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. Int J Biol Markers 15(3):226–230, 2000
Fletcher R, Fletcher S, Wagner E: Clinical Epidemiology: The Essenctials. Third ed. Philadelphia: Williams & Williams, 1996.